CN102827153B - 阿齐沙坦的晶型及其制备方法 - Google Patents
阿齐沙坦的晶型及其制备方法 Download PDFInfo
- Publication number
- CN102827153B CN102827153B CN201110158635.0A CN201110158635A CN102827153B CN 102827153 B CN102827153 B CN 102827153B CN 201110158635 A CN201110158635 A CN 201110158635A CN 102827153 B CN102827153 B CN 102827153B
- Authority
- CN
- China
- Prior art keywords
- crystal formation
- azilsartan
- preparation
- compound
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 27
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 24
- 239000005485 Azilsartan Substances 0.000 title claims abstract description 19
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 229960002731 azilsartan Drugs 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 11
- 206010020772 Hypertension Diseases 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 208000027796 Blood pressure disease Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- -1 under stirring Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Abstract
Description
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110158635.0A CN102827153B (zh) | 2011-06-14 | 2011-06-14 | 阿齐沙坦的晶型及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110158635.0A CN102827153B (zh) | 2011-06-14 | 2011-06-14 | 阿齐沙坦的晶型及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102827153A CN102827153A (zh) | 2012-12-19 |
| CN102827153B true CN102827153B (zh) | 2016-10-05 |
Family
ID=47330490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110158635.0A Active CN102827153B (zh) | 2011-06-14 | 2011-06-14 | 阿齐沙坦的晶型及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102827153B (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2760859A1 (en) * | 2011-09-30 | 2014-08-06 | Sunshine Lake Pharma Co., Ltd | Crystalline forms of azilsartan and preparation and uses thereof |
| CN102766139B (zh) * | 2012-08-14 | 2014-09-17 | 江苏先声药物研究有限公司 | 阿齐沙坦的多晶型物及其制备方法 |
| CN103044412B (zh) * | 2012-12-26 | 2016-04-06 | 华润赛科药业有限责任公司 | 一种阿齐沙坦的多晶型及其制备方法 |
| CN103319473A (zh) * | 2013-07-02 | 2013-09-25 | 合肥医工医药有限公司 | 阿齐沙坦的多晶型及其制备方法 |
| CN104341408A (zh) * | 2013-08-02 | 2015-02-11 | 江苏柯菲平医药股份有限公司 | 一种阿奇沙坦的新晶型及其制备方法 |
| CN103664921B (zh) * | 2013-11-27 | 2016-08-24 | 湖南千金湘江药业股份有限公司 | 一种阿齐沙坦晶型a及其制备方法 |
| CN104262334A (zh) * | 2014-09-16 | 2015-01-07 | 常州大学 | 一种阿奇沙坦晶体及其制备方法 |
| CN104557899B (zh) * | 2014-11-17 | 2018-05-22 | 江苏中邦制药有限公司 | 一种阿齐沙坦i晶型晶体的制备方法 |
| CN106749217A (zh) * | 2017-01-22 | 2017-05-31 | 鲁南制药集团股份有限公司 | 一种阿齐沙坦i晶型 |
| CN110041320B (zh) * | 2019-04-24 | 2020-11-20 | 浙江天宇药业股份有限公司 | 一种阿齐沙坦的结晶的制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1067890A (zh) * | 1991-06-27 | 1993-01-13 | 武田药品工业株式会社 | 杂环化合物，其制备及应用 |
| WO2006107062A2 (en) * | 2005-03-30 | 2006-10-12 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use as angiotensin ii antagonist |
| US7157584B2 (en) * | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
-
2011
- 2011-06-14 CN CN201110158635.0A patent/CN102827153B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1067890A (zh) * | 1991-06-27 | 1993-01-13 | 武田药品工业株式会社 | 杂环化合物，其制备及应用 |
| US7157584B2 (en) * | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
| WO2006107062A2 (en) * | 2005-03-30 | 2006-10-12 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use as angiotensin ii antagonist |
Non-Patent Citations (1)
| Title |
|---|
| 阿奇沙坦的合成;束蓓艳，等;《中国医药工业杂志》;20101231;第41卷(第12期);第881-883页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102827153A (zh) | 2012-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102827153B (zh) | 阿齐沙坦的晶型及其制备方法 | |
| CN104262324A (zh) | 5-氯-n2-(2-异丙氧基-5-甲基-4-哌啶-4-基-苯基)-n4-[2-(丙烷-2-磺酰基)-苯基]-嘧啶-2,4-二胺的结晶形式 | |
| CN105209437A (zh) | 心肌肌球蛋白激动剂的盐和制备盐的方法 | |
| JP2009542787A5 (zh) | ||
| AU2013330603B2 (en) | Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same | |
| CN103153981B (zh) | (4‑{4‑[5‑(6‑三氟甲基‑吡啶‑3‑基氨基)‑吡啶‑2‑基]‑苯基}‑环己基)‑乙酸钠盐的结晶型 | |
| CN104592195A (zh) | 一种苯甲酸阿格列汀的制备方法 | |
| CN104736540B (zh) | 培美曲塞及其赖氨酸盐的制备方法 | |
| CN104788438A (zh) | 恩格列净b晶型及其制备 | |
| JP2015508090A (ja) | 固体形態のダビガトランエテキシレートメシレート及びその調製方法 | |
| CN103664922A (zh) | 新晶型阿齐沙坦及其制备方法 | |
| CN104744464A (zh) | 伊曲茶碱晶型 | |
| WO2013174035A1 (zh) | 一种制备磷酸西他列汀无水晶型i的方法 | |
| CN104721828A (zh) | 一种改善晶体药物稳定性的药物组合物及其制备方法 | |
| CN104774197B (zh) | 一种苯并咪唑衍生物的制备方法 | |
| CN102070558B (zh) | 非布索坦的新晶型及其制备方法 | |
| CN103242291A (zh) | 一种多晶型高含量苯甲酸阿格列汀的批量生产工艺 | |
| WO2012171377A1 (zh) | 一类积雪草酸氨丁三醇盐晶型及其制备方法 | |
| CN108129486B (zh) | 嘧啶酮衍生物及其用途 | |
| CN103626722B (zh) | 一氧化氮供体型降血糖化合物、其制备方法和用途 | |
| CN104151299B (zh) | 化合物、晶型化合物及其制备方法 | |
| CN104725377B (zh) | 一种盐酸莫西沙星的晶型及其制备方法 | |
| CN108863946B (zh) | 一种地巴唑杂质对照品的制备方法 | |
| CN102018705A (zh) | 一种含有非布司他晶体的药物组合物及制备方法 | |
| CN107382922A (zh) | 高透光度盐酸雷尼替丁的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant after: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL Co.,Ltd. |
|
| COR | Change of bibliographic data | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB02 | Change of applicant information |
Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant after: Jiangsu best Pharmaceutical Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: Jiangsu best Pharmaceutical Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160318 Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121219 Assignee: JIANGXI SYNERGY PHARMACEUTICAL CO.,LTD. Assignor: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Contract record no.: X2023980034034 Denomination of invention: The crystal form of azilsartan and its preparation method Granted publication date: 20161005 License type: Common License Record date: 20230324 |